Y Intercept Hong Kong Ltd Makes New $1.79 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

Y Intercept Hong Kong Ltd purchased a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 40,706 shares of the company's stock, valued at approximately $1,787,000. Y Intercept Hong Kong Ltd owned approximately 0.07% of Structure Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GPCR. Bank of Montreal Can purchased a new stake in shares of Structure Therapeutics in the second quarter worth approximately $1,064,000. Lighthouse Investment Partners LLC purchased a new stake in Structure Therapeutics in the 2nd quarter worth approximately $1,178,000. Vestal Point Capital LP boosted its stake in shares of Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company's stock valued at $50,474,000 after buying an additional 590,000 shares during the period. abrdn plc grew its holdings in shares of Structure Therapeutics by 132.7% during the 3rd quarter. abrdn plc now owns 217,083 shares of the company's stock valued at $9,528,000 after acquiring an additional 123,789 shares in the last quarter. Finally, Pier Capital LLC increased its stake in shares of Structure Therapeutics by 32.7% in the third quarter. Pier Capital LLC now owns 134,291 shares of the company's stock worth $5,894,000 after acquiring an additional 33,087 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on GPCR. Morgan Stanley began coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an "overweight" rating and a $118.00 price objective for the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, HC Wainwright assumed coverage on shares of Structure Therapeutics in a research report on Wednesday, December 4th. They set a "buy" rating and a $80.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics has a consensus rating of "Buy" and an average price target of $85.67.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR traded down $0.45 during mid-day trading on Wednesday, reaching $34.25. 1,017,688 shares of the company traded hands, compared to its average volume of 788,642. The company's fifty day moving average is $36.77 and its two-hundred day moving average is $39.27. Structure Therapeutics Inc. has a fifty-two week low of $26.61 and a fifty-two week high of $62.74. The stock has a market cap of $1.96 billion, a PE ratio of -46.28 and a beta of -3.41.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.